Brief: Unicycive Therapeutics Announces Orphan Drug Designation Granted for UNI-494 by The FDA
04/03/2024 12:13
March 4 (Reuters) - Unicycive Therapeutics Inc UNCY.O :
* UNICYCIVE THERAPEUTICS ANNOUNCES ORPHAN DRUG DESIGNATION
GRANTED
FOR UNI-494 BY THE U.S. FOOD AND DRUG ADMINISTRATION FOR THE
PREVENTION OF DELAYED GRAFT FUNCTION IN KIDNEY TRANSPLANT
PATIENTS
Source text for Eikon: ID:nGNX6FgVc4
Further company coverage: UNCY.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Unicycive Therapeutics
See all newsBrief: Unicycive Therapeutics Appoints Meredith Manning To Board Of Directors
Brief: Unicycive Therapeutics Announces Resubmission Of New Drug Application For Oxylanthanum Carbonate
U.S. RESEARCH ROUNDUP-Airbnb, Five Below, Silgan Holdings
U.S. STOCKS ON THE MOVE-Sutro Biopharma, Humacyte, CoreWeave
Unicycive rises on narrower quarterly loss